1. Introduction {#sec1}
===============

Microsatellite instability (MSI) or mismatch repair deficient (dMMR) is one of the main pathogenetic pathways leading to the development of colorectal cancer \[[@B1]\]. MSI phenotype is due to dysfunction of a DNA mismatch repair (MMR) system in microsatellite replication \[[@B2]\]. The MMR system is composed of four MMR genes and their encoded proteins (MLH1, MSH2, MSH6, and PMS2) \[[@B3]\]. These proteins form heterodimers that repair DNA damage (mismatches as well as short insertion or deletion loops) \[[@B4]\]. In hereditary nonpolyposis CCRs (e.g., Lynch syndrome), 90% of the MMR alterations are mainly due to constitutional mutations of the MLH1 and MSH2 gene (more rarely MSH6 or PMS2 gene) or alteration in EPCAM (TACSTD1) gene that causes epigenetic silencing of MSH2 \[[@B5], [@B6]\], while 10 to 15% of all sporadic CCRs are due to hypermethylation of CpG islands in the MLH1 promoter \[[@B6]\].

Several studies have shown that dMMR tumors have special clinicopathological features, including poor differentiation, right colon location, abundant tumor-infiltrating lymphocytes, and mucinous histology \[[@B7]\]. Furthermore, these tumors are associated with the presence of BRAF mutations \[[@B8]\]. MMR tumors are diagnosed in 15-20% of localized CCRs, especially in stage II, although they represent 3-5% of metastatic CCRs \[[@B9]\].

Variable results are reported in the literature, about the association between MSI status and survival in colorectal cancer. Tumors diagnosed at stage II or III with MSI have better prognosis than MSS tumors \[[@B10], [@B11]\]. In addition, many studies have demonstrated that CCRs with MSI status showed poorer response to 5-fluorouracil (5FU) compared to CCRs with MSS status \[[@B10]\]. For patients with stage III and MSI, it has been confirmed that only those with suspected germinal mutations can benefit from treatment with 5FU \[[@B11]\].

In the Moroccan population, few studies have reported the prognostic factors of MSI colon cancer. Therefore, in this study, we aimed to assess the frequency of loss in MMR protein expression, to compare the clinical and pathological features of MSI versus MSS colon cancers, and to evaluate the survival rates in patients with MSI tumors in association with other clinicopathological features, for the first time in the FES population.

2. Materials and Methods {#sec2}
========================

2.1. Ethics {#sec2.1}
-----------

This study protocol was reviewed and approved by Hassan II University Hospital Ethics Committee of FEZ, Morocco, under reference no. 13/18. All patients gave informed consent before the start of the study.

A total of 330 patients diagnosed with colon cancer were included in this study, in the Department of Pathology of Hassan II University Hospital, Fez, Morocco, from 2013 to 2019. Medical charts have been reviewed, and patients have been selected using the following selection criteria: (a) patients had histologically confirmed primary adenocarcinoma (b) all cases with pathologic stage I-IV colon cancer and underwent surgical resection for CC tumor. However, patients were excluded if their records were incomplete and without histological confirmation of colon adenocarcinoma and if they had rectal cancer ([Figure 1](#fig1){ref-type="fig"}).

The clinical and pathological data including age, gender, main histological pattern, tumor grade, tumor stage, numbers of dissected regional lymph nodes, family history of colon cancer, follow-up, and outcome have been obtained from the patient\'s medical records and pathology reports.

2.2. Identification of HNCCP Patients {#sec2.2}
-------------------------------------

Family history and clinical data were reviewed to determine patients who fulfilled the Amsterdam (I-II) criteria and met the Bethesda guidelines for molecular Lynch syndrome (LS) testing. However, any patient did fulfill the clinical features concerning for LS.

2.3. Detection of MMR Protein Expression by Immunohistochemistry {#sec2.3}
----------------------------------------------------------------

The mismatch repair tumor status (MSS or MSI) was assessed by immunohistochemistry (IHC) to detect the intact or the loss expression of the MMR proteins (MLH1, PMS2, MSH2, and MSH6).

The IHC study was assessed on unstained formalin-fixed paraffin-embedded (FFPE) tumor tissue sections of 5 *μ*m thickness, on the automated immunostainer Ventana Benchmark ULTRA. We have employed monoclonal antibodies specific for each MMR protein, MLH1 (G168-728/CELL MARQUE), MSH2 (G219-1129/CELL MARQUE), MSH6 (44/CELL MARQUE), and PMS2 (MRQ-28/CELL MARQUE). Adjacent normal tissue (lymphocytes or normal glandular cells) was used as an internal control for positive staining (should always show staining).

2.4. Full RAS and BRAF Mutation Analysis {#sec2.4}
----------------------------------------

### 2.4.1. Genomic DNA Extraction {#sec2.4.1}

Tumoral DNA was extracted from paraffin-embedded tumor sections. The blocks with higher proportion of tumors cells were selected by a pathologist on hematoxylin-, safran-, and eosin-stained slides. From the selected FFPE tumor block, 4--8 sections of 5 *μ*m thickness were obtained for DNA extraction using the QIAamp DNA FFPE Tissue Kit (Invitrogen), according to the manufacturer\'s instructions.

### 2.4.2. BRAF Mutation Analysis {#sec2.4.2}

BRAF testing was performed for 200 patents, using Sanger sequencing to distinguish sporadic dMMR CC that exhibits the V600E mutation in the BRAF oncogene. DNA was amplified using PCR (Master Mix (2X) kits) according to the manufacturer\'s protocols. The purified PCR products were sequenced using the direct sequencing with BigDye Terminator V3.1 Cycle Sequencing Kit (ABI Prism) and analyzed on Applied Biosystems 3500Dx Genetic Analyzer (Applied Biosystems).

### 2.4.3. RAS Mutation Analysis {#sec2.4.3}

KRAS and NRAS molecular testing was performed using Sanger sequencing and pyrosequencing methods. Pyrosequencing was performed on the Qiagen PyroMark Q24 device according to the CE-IVD-marked therascreen RAS Pyro Kit Handbook. Sanger sequencing was performed as described previously (BRAF mutation testing).

2.5. Statistical Analysis {#sec2.5}
-------------------------

Statistical analysis was performed using IBM SPSS Version 20.0. The associations between the clinicopathological features of tumors and the microsatellite status (MSI/MSS) were evaluated using a chi-square test or Fisher exact tests. Tests were statistically significant when *P* \< 0.05. An unpaired t-test with Welch\'s correction was used to analyze continuous data. Survival rates were analyzed using the Kaplan--Meier method, and survival curves were compared with the log-rank test. Analysis was performed using a Cox proportional hazard model to identify prognostic factors. Factors that were significant in univariate analysis were included in the multivariate model.

3. Results {#sec3}
==========

3.1. Patient Characteristics {#sec3.1}
----------------------------

The mean age was 54.62 years (range of 16-90 years). There was a slight predominance of male gender with 174 (52.7%) men and 156 (47.3%) women patients. The left colon was the most frequent site of CC in our population (*n* = 254, 77%), while the right colon was diagnosed in 76 cases (23%). Adenocarcinoma was the main histological type of CC in our study with 278 (84.2%) cases. The moderate and the well differentiation grades were found, respectively, in 128 (38.9%) cases and 173 (52.6%) cases, despite the fact that only 28 (8.5%) cases were poorly differentiated. Regarding the pathologic stage of tumors, 161 (48.8%) were stage II, 73 (22.1%) were stage III, 68 (20.6%) were stage IV, and 28 were stage I (8.5%). 68 (20.6%) patients were classified as the metastatic group. All clinicopathological features of patients are summarized in [Table 1](#tab1){ref-type="table"}.

Among the total of 330 colon cancer (CC) patients who prospectively tested for microsatellite instability during the study period, 293 were MSS (88.8%) and 37 MSI (11.2%) ([Figure 2](#fig2){ref-type="fig"}). Of the 37 MSI tumors, the loss of expression of MMR proteins was as follows: MLH1/PMS2 (*n* = 18) (5.4%), MSH2/MSH6 (*n* = 11) (3.3%), MSH6 (*n* = 1) (0.3%), PMS2 (*n* = 3) (1%), and MLH1 (*n* = 4) (1.3%).

3.2. BRAF, KRAS, and NRAS Analyses {#sec3.2}
----------------------------------

### 3.2.1. BRAF Analysis {#sec3.2.1}

BRAF V600E mutation testing was performed on all patients with MSI tumors (37 patients) and on 163 patients with MSS tumors, while we did not find any case with both *MLH1* protein expression loss and BRAF mutation.

### 3.2.2. KRAS and NRAS Analyses {#sec3.2.2}

RAS analysis was performed in 116 patients. We detected KRAS exon 2 mutations in 36 patients (33.3%). Among the 80 patients with KRAS exon 2 wild-type (69.0%), we identified two mutations in KRAS exon 4 (codon 146 (1.7%)). However, no mutation was detected in the NRAS gene (0%) ([Figure 3](#fig3){ref-type="fig"}).

3.3. Pathological Features of MSI Tumors {#sec3.3}
----------------------------------------

A summary of the main clinicopathological features of MSI cancers compared to MSS cancers is shown in [Table 2](#tab2){ref-type="table"}. In the majority of cases, tumors with MSI were located in the right colon compared to MSS tumors (*P* ≤ 0.001). Male gender was significantly associated with MSI tumors (72.0% versus 28.0%, *P* = 0.04). Moreover, MSI tumors were more commonly found in patients under 57 years (*P* = 0.05). As for distant metastases, no patient with MSI status had distant metastases at the time of diagnostic, and the difference was statistically significant (*P* = 0.03). Regarding pathologic disease stage, stage I-II were more common in MSI tumors (*P* = 0.02). Histologically, the degree of differentiation was associated with MSI tumors and the difference was statistically significant (*P* = 0.04). In contrast, no significant correlation was found between MSI tumors and histologic subtype, T stage, vascular invasion, perineural invasion, family history of colon cancer, and RAS mutation.

3.4. Nodal Counts in Stage I-IV Colon Cancer: Comparison of the Total Lymph Nodes (LNs), Metastatic LNs, and LNR according to MSI Status {#sec3.4}
----------------------------------------------------------------------------------------------------------------------------------------

When analyzing our cohort, MSI tumors were associated with a significantly higher total LN count (mean: 23.440 vs. 19.075, *P* = 0.04). However, the number of positive LNs was significantly lower in MSI patients (mean: 0.28 vs. 1.34, *P* = 0.007). The LNR was also lower in MSI tumors, and the difference was statistically significant (0.01 vs. 0.08, *P* = 0.01). The lymph node characteristics of MSI tumors are compiled in [Table 3](#tab3){ref-type="table"}.

When analyzing our cohort, MSI tumors were associated with a significantly higher total LN count (mean: 21.08 vs. 17.68, *P* = 0.04). However, the number of positive LNs was significantly lower in MSI patients (mean: 0.62 vs. 1.33, *P* = 0.03). The LNR was also lower in MSI tumors, and the difference was statistically significant (0.03 vs. 0.08, *P* = 0.02). The lymph node characteristics of MSI tumors are compiled in [Table 3](#tab3){ref-type="table"}.

3.5. Clinicopathological Features of Patients with Right Colon Cancer and Left Colon Cancer {#sec3.5}
-------------------------------------------------------------------------------------------

[Table 4](#tab4){ref-type="table"} shows the basic characteristics between the right colon cancer (RCC) and the left colon cancer (LCC). The mean age of right-sided tumors was significantly younger than that of left-sided tumors (52.5 and 58.5 years old, respectively, *P* = 0.01). Patients with RCC were significantly more likely to be male in our study (*P* = 0.03). Regarding pathologic grade, moderate differentiated tumors were less common in RCC than in LCC patients (*P* = 0.05). In addition, a mucinous adenocarcinoma subtype was significantly associated with RCC tumors than with LCC tumors (*P* = 0.01). At all stages, the mean of harvested lymph nodes was significantly higher in RC tumors than in LCC tumors (22.2 vs. 18.17, *P* = 0.01). More LCC had a higher incidence of metastatic disease at diagnosis (15.8% vs. 6.3%, *P* = 0.05). In this study, 30.2% of RCC patients were microsatellite unstable compared to 5.9% of LCC patients (*P* ≤ 0.001). The frequency of RAS mutation did not differ between RCC tumors and LCC tumors in our study.

3.6. Comparison of Clinicopathological Features between Patients Less than 58 Years Old and Older {#sec3.6}
-------------------------------------------------------------------------------------------------

As shown in [Table 5](#tab5){ref-type="table"}, we divided the patients into two groups: patients who were 57 years old and less and patients more than 57 years old. The proportion of right colon cancers was higher in patients 57 years old and less than in older patients (*P* = 0.02). The proportion of poorly differentiated tumors was higher in the youngest age subgroup than in the oldest (11.8% vs. 5.0%, *P* = 0.05). Interestingly, the presence of a family history of colon cancer was significantly associated with the youngest age subgroup (*P* = 0.02). The youngest age subgroup had more nodes examined than the oldest age subgroup (*P* \< 0.001). Moreover, 90.7% of the youngest patients have more than 12 lymph nodes collected, compared with 80.6% in the oldest patients (*P* = 0.04). Generally, the MSI status was also significantly correlated with the youngest age subgroup in our series (*P* = 0.01).

4. Survival Analysis {#sec4}
====================

The median length of the follow-up period was 30.00 months (range 0-117 months). From 330 patients\' colon cancer, 33 patients (10%) developed distant metastasis during the follow-up period. The time to metastasis ranged from 2 to 46 months (median = 11.00 months). The most common metastatic site was peritoneum (*n* = 13, 43.3%) followed by the lung (*n* = 11, 36.6%), liver (*n* = 10, 33.3%), Os (*n* = 1, 3.3%), ovary (*n* = 1, 3.3%), distant lymph nodes (*n* = 1, 3.3%), and head (*n* = 1, 3.3%). Regarding recidivism, 9 of 330 patients developed a disease relapse. The median length of recidivism was 11.0 months (range 0-29 months).

According to our findings in our cohort, we observed a better prognosis of MSI patients compared with that of MSS patients and the difference was statistically significant (109.71% vs. 74.08%, *P* = 0.001) ([Figure 4(a)](#fig4){ref-type="fig"}). The variables associated with the OS are shown in [Table 6](#tab6){ref-type="table"}. On univariate analysis, the male gender was significantly associated with OS (*P* = 0.003) ([Figure 4(b)](#fig4){ref-type="fig"}). The OS of patients with stage III-IV disease was significantly lower than that of patients with stage I-II disease (63.85% vs. 89.48%, *P* = 0.000) ([Figure 4(d)](#fig4){ref-type="fig"}). Moreover, right localization and male gender were found to be statistically significant predictors of poor outcomes in our population ([Figure 4(c)](#fig4){ref-type="fig"}). Interestingly, we stratified the LNR into 2 subgroups based on the mean value of 0.07, and we documented that the higher value of LNR was a better predictor of prognosis (*P* = 0.03) ([Figure 4(e)](#fig4){ref-type="fig"}).

Cox proportional hazard regression was performed for factors that were significant in univariate analysis (*P* \< 0.05) (MSI status, gender, tumor site, disease stage, and LNR). Multivariate analysis revealed that female gender, left localization, and III-IV were the independent poor prognostic factors for OS in colon cancer [Table 6](#tab6){ref-type="table"}.

5. Discussion {#sec5}
=============

In the present study, we aimed to evaluate the impact of MSI status and clinicopathological features on overall survival in the Moroccan population. Our findings suggest that MSI tumors occur in 11.2% in the FES population which is similar to previous studies which confirmed that the rate of dMMR tumors in colon cancer is between 10% and 15% \[[@B12], [@B13]\]. In addition, we observed that MSI tumors were commonly found in younger patients (≤57) and in the right colon as reported in the literature \[[@B13], [@B14]\]. In line with other studies \[[@B10], [@B14], [@B15]\], we found that MSI tumors were mostly diagnosed in stage II (75.7%). This finding could explain the more favorable prognosis of MSI subtype, described in several studies \[[@B14], [@B16]\].

Our study has been able to demonstrate a positive relationship between MSI tumors and total lymph node count. Recently, Tian et al. \[[@B13]\] found the same observation in a cohort of 1250 stage II-IV CRC cases. These findings are a possible explanation for the high immune response observed in MSI tumors \[[@B17], [@B18]\]. In addition, the patients enrolled in our study showed a significantly lower rate of positive lymph node. The low lymph node ratio (LNR) was also associated with MSI tumors in all stages of CC. This finding is in line with the results reported by Ghanipour et al. \[[@B15]\] in a recent publication which indicated a relevant association between MSI high and low rate of LNR. A previous study documented that low LNR is a predictor of good outcome \[[@B19], [@B20]\]. These results explain the better survival of patients with MSI status. Despite better outcomes, our study showed a positive correlation between MSI status and poor differentiation, which is reported as a factor of poor prognosis. This result is in agreement with several reports \[[@B21]--[@B23]\].

In our study, from 200 patients, we did not find any *BRAF* mutation in both MSI and MSS tumors. This result confirms the rarity of the V600E mutation in colon cancer, epically in the Moroccan population \[[@B17]\].

On the other hand, many investigators demonstrate that RCC and LCC show clinicopathological and molecular differences. In the present study, RCC tumors are more likely mucinous, commonly observed in younger patients, had less metastasis disease, and showed frequently MSI status. In univariate and multivariate analyses, we found that RCC had better OS than LCC and the significant difference of the Cox hazard ratio between the two subgroups was reported in our series (*P* = 0.05). Some studies have documented that overall survival is generally worse in the right colon compared to the left colon \[[@B24], [@B25]\], while others revealed no difference \[[@B18]\]. The molecular profile of right colon cancer characterized by the presence of RAS/BRAF mutation which correlated with worse outcome \[[@B26]\]. In the present study, there was no association between RC location and RAS mutation.

The relationship between MSI tumors and OS is unclear according to Elias et al. \[[@B19]\]. In our study, there was an improved OS in patients with stage I-IV and MSI status. In line with our findings, previous studies have demonstrated that MSI tumors have a better clinical outcome \[[@B27]\]. The prognosis value of MSI tumors could be explained by the low rate of metastasis at diagnosis observed in these tumors, which is confirmed in our study. Indeed, Ferri et al. \[[@B21]\] have reported that the MSI patients with locally advanced colorectal cancers had a better prognosis.

According to many studies, low LNR was proven to be a strong prognostic factor of survival \[[@B20], [@B26]\]. In addition, Emterling et al. \[[@B22]\] documented a significant association between higher LNR and reduced OS and time to recurrence in patients with stage III of CRC. In our study, we found an improved OS in patients with low LNR, with a significant statistical difference on univariate analysis (*P* = 0.03), although TLN was not found to be an independent prognostic factor in our series on both univariate and multivariate analyses. In line with our results, Jass et al. \[[@B23]\] reported no significant difference of the Cox hazard ratio between OS and TLN.

Reviewing our data, we found that patients who were diagnosed with stage III-IV disease had the highest risk of death compared to those with stage I-II disease. Our results are in agreement with the finding recently reported by Weiss et al. \[[@B24]\]. Interestingly and contrary to previous studies \[[@B28], [@B29]\], we documented a strong significant correlation between male gender and OS in all stages, while other reports did not find any difference in survival between genders \[[@B30], [@B31]\]. Our result may be related to the proportions of colon cancer patients included in our study and the stronger correlation observed between MSI status and male gender. Moreover, the multivariate analysis revealed that MSI status, right localization, stage I-II, and male gender were the most significant prognostic factors for overall survival in Moroccan patients.

6. Conclusion {#sec6}
=============

In summary, our study demonstrates that patients with MSI status have particular clinicopathological features like TLN, LNR, poor differentiation, right colon, locally advanced tumors, male gender, and younger patients. The results of survival analysis indicate that MSI status was not predictive of improved overall survival in our context with a lower statistical significance (*P* = 0.05). After cox regression analysis, the right localization of the tumor, I-II stage disease, and male gender showed a trend toward a better prognosis in our population.
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![Immunohistochemical staining for MMR proteins. (a) Overexpression of MLH1 protein in colon adenocarcinoma (magnification 200x). (b) MLH1 loss in colon adenocarcinoma (magnification 200x).](DM2019-3210710.002){#fig2}

![Direct sequencing chromatograms. (a) *KRAS* exon 2 mutation (c.35G\>A, p.G12D change), (b) *KRAS* exon 4 mutation (c.436 G\>A, p.A146T change).](DM2019-3210710.003){#fig3}

![The Kaplan--Meier overall survival curve of the 330 colon cancer patients according to different variables: (a) MSI status, (b) Gender, (c) tumor localization, (d) disease stage, and (e) LNR.](DM2019-3210710.004){#fig4}

###### 

Clinicopathological features of 330 patients.

  Variables                  *N* (%)
  -------------------------- --------------------
  Age (mean)                 54.62 years ± 14.7
   \<50                      123 (37.3%)
   \>50                      207 (62.7%)
  Sex                        
   Female                    156 (47.3%)
   Male                      174 (52.7%)
  Tumor site                 
   Right colon               76 (23.0%)
   Left colon                254 (77.0%)
  Histologic subtype         
   Adenocarcinoma            278 (84.2%)
   Mucinous adenocarcinoma   29 (8.8%)
   Others                    23 (7%)
  Histologic grade           
   Well                      173 (52.4%)
   Moderate                  128 (38.8%)
   Poor                      28 (8.5%)
   Unknown                   1 (0.3%)
  Perineural invasion        
   Yes                       27 (8.2%)
   No                        272 (82.4%)
   Unknown                   31 (9.4%)
  Vascular invasion          
   Yes                       39 (11.8%)
   No                        291 (88.2%)
  Disease stage              
   I                         28 (8.5%)
   II                        161 (48.4%)
   III                       73 (22.1%)
   IV                        68 (20.6%)
  MSI status                 
   MSS                       293 (88.8%)
   MSI                       37 (11.2%)

*N*: number of cases; SD: standard deviation; MSS: microsatellite stable; MSI: microsatellite instability.

###### 

Clinicopathological features of MSI cancers.

  Characteristics            Defect MMR      Intact MMR      *P* value
  -------------------------- --------------- --------------- -----------
  Age                                                        
  Mean                       51.5 (±14.18)   55.0 (±15.45)   0.1
   ≤57                       26 (70.3%)      144 (49.1%)     **0.01**
   ≥57                       11 (29.7%)      149 (50.9%)     
  Gender                                                     
   Female                    10 (27.0%)      146 (49.8%)     **0.007**
   Male                      27 (73.0%)      147 (50.2%)     
  Tumor site                                                 
   Right colon               23 (62.2%)      53 (18.1%)      **0.000**
   Left colon                14 (37.8%)      240 (81.9%)     
  Histologic subtype                                         
   Adenocarcinoma            30 (81.8%)      248 (84.6%)     
   Mucinous adenocarcinoma   6 (16.2%)       23 (7.8%)       **0.1**
   Others                    1 (2.7%)        22 (7.5%)       
  Histologic grade                                           
   Well                      15 (40.5%)      208 (71.5%)     **0.000**
   Poor                      22 (59.5%)      83 (28.5%)      
  Vascular invasion                                          
   Yes                       7 (18.9%)       32 (10.9%)      **0.1**
   No                        30 (81.1%)      261 (89.1%)     
  Perineural invasion                                        
   Yes                       2 (5.7%)        25 (9.5%)       **0.3**
   No                        33 (94.3%)      239 (90.5%)     
  Family history of cancer                                   
   Yes                       3 (8.1%)        9 (3.1%)        **0.1**
   No                        34 (91.9%)      284 (96.9%)     
  Tumor stage (T)                                            
   T1                        0 (0.0%)        4 (1.3%)        **0.5**
   T2                        5 (13.5%)       47 (16.2%)      
   T3                        25 (67.6%)      173 (59.5%)     
   T4                        7 (18.9%)       67 (23.0%)      
  Distant metastases (M)                                     
   M0                        36 (97.3%)      222 (76.8%)     **0.001**
   M1                        1 (2.7%)        67 (23.2%)      
  Disease stages                                             
   I-II                      28 (75.7%)      160 (54.6%)     **0.01**
   III-IV                    9 (24.3%)       133 (45.4%)     
  RAS mutation                                               
   Presence                  6 (15.8%)       32 (84.2%)      **0.09**
   Absence                   12 (15.4%)      66 (84.6%)      

MMR: mismatch repair; SD: standard deviation.

###### 

Comparison of lymph node features according to MSI status.

                     MSI (*n* = 37)   MSS (*n* = 293)   *P* value (95% CI)
  ------------------ ---------------- ----------------- ------------------------------
  Total node                                            
  Mean (SD)          21.08 (±9.94)    17.68 (±9.54)     *P* = 0.04 (0.053 to 6.74)
  Positive node      0.62 (±1.49)     1.33 (±3.10)      *P* = 0.03 (-1.35 to -0.005)
  Lymph node ratio   0.03 (±0.08)     0.08 (±0.27)      *P* = 0.02(-0.097 to -0.005)

MSI: microsatellite instability; MSS: microsatellite stable; SD: standard deviation.

###### 

Comparison of clinicopathological characteristics between the right colon and left colon.

  Characteristics            Right colon      Left colon      *P* value
  -------------------------- ---------------- --------------- ------------
  Age                                                         
  Mean (SD)                  51.4 (±15.7)     55.5 (±15.0)    **0.03**
   ≤57                       47 (61.8%)       123 (48.4%)     **0.002**
   ≥57                       29 (38.2%)       131 (51.6%)     
  Gender                                                      
   Female                    28 (36.8%)       128 (50.4%)     **0.02**
   Male                      48 (63.2%)       126 (49.6%)     
  Histologic subtype                                          
   Adenocarcinoma            59 (77.6%)       219 (86.2%)     **0.04**
   Mucinous adenocarcinoma   12 (15.8%)       17 (6.7%)       
   Others                    5 (6.6%)         18 (7.1%)       
  Histologic grade                                            
   Well                      42 (55.3%)       131 (51.8%)     **0.05**
   Moderate                  26 (34.2%)       102 (40.3%)     
   Poor                      8 (10.5%)        20 (7.9%)       
  Vascular invasion                                           
   Yes                       14 (18.4%)       25 (9.8%)       **0.03**
   No                        62 (81.6%)       229 (90.2%)     
  Perineural invasion                                         
   Yes                       7 (9.2%)         20 (9.0%)       **0.5**
   No                        69 (90.8%)       203 (91.0%)     
  Total lymph node                                            
  Mean (SD)                  20.67 (±11.28)   17.28 (±8.85)   **0.01**
   LN \> 12                  53 (74.7%)       82 (46.7%)      **0.000**
   LN \< 12                  18 (25.3%)       105 (53.3%)     
  Family history of cancer                                    
   Yes                       5 (6.6%)         7 (2.8%)        **0.1**
   No                        71 (93.4%)       247 (97.2%)     
  Tumor stage (T)                                             
   T1                        1 (1.3%)         3 (1.2%)        **0.8**
   T2                        10 (13.2%)       42 (16.7%)      
   T3                        48 (63.2%)       150 (59.5%)     
   T4                        17 (22.4%)       57 (22.6%)      
  Distant metastases (M)                                      
   M0                        68 (91.9%)       190 (75.4%)     **0.001**
   M1                        6 (8.1%)         68 (24.6%)      
  Disease stages                                              
   I                         9 (11.8%)        19 (7.5%)       **0.002**
   II                        45 (59.2%)       116 (45.7%)     
   III                       17 (22.4%)       56 (22.0%)      
   IV                        5 (6.6%)         63 (24.8%)      
  MSI status                                                  
   MSI                       23 (30.3%)       14 (5.5%)       **0.0000**
   MSS                       53 (69.7%)       240 (94.5%)     
  RAS mutation                                                
   Presence                  13 (34.2%)       25 (65.8%)      **0.4**
   Absence                   22 (28.2%)       56 (71.8%)      

SD: standard deviation; LN: lymph node; MSI: microsatellite instability; MSS: microsatellite stable.

###### 

Comparison of clinicopathological parameters between patients less than 57 years old and older patients.

  Characteristics            ≤57             ≥57            *P* value
  -------------------------- --------------- -------------- -----------
  Gender                                                    
   Female                    88 (51.8%)      68 (42.5%)     **0.05**
   Male                      82 (48.2%)      92 (57.5%)     
  Tumor site                                                
   Right colon               47 (27.6%)      29 (18.1%)     **0.02**
   Left colon                123 (72.4%)     131 (81.9%)    
  Histologic subtype                                        
   Adenocarcinoma            138 (81.2%)     140 (87.5%)    **0.07**
   Mucinous adenocarcinoma   15 (8.8%)       14 (8.8%)      
   Others                    17 (10.0%)      6 (3.8%)       
  Histologic grade                                          
   Well                      88 (52.1%)      85 (53.1%)     **0.05**
   Moderate                  61 (36.1%)      67 (41.9%)     
   Poor                      20 (11.8%)      8 (5.0%)       
  Vascular invasion                                         
   Yes                       16 (9.4%)       23 (14.4%)     **0.1**
   No                        154 (90.6%)     137 (85.6%)    
  Perineural invasion                                       
   Yes                       14 (9.1%)       13 (9.0%)      **0.5**
   No                        140 (90.9%)     132 (91.0%)    
  Total lymph node                                          
  Mean (SD)                  24.5 (±10.30)   17.9 (±9.06)   **0.000**
   LN \> 12                  68 (90.7%)      58 (80.6%)     **0.04**
   LN \< 12                  7 (9.3%)        14 (19.4%)     
  Family history of cancer                                  
   Yes                       9 (5.3%)        3 (1.9%)       **0.02**
   No                        161 (94.7%)     157 (98.1%)    
  Tumor stage (T)                                           
   T1                        3 (0.0%)        1 (0.6%)       **0.4**
   T2                        22 (13.1%)      30 (18.8%)     
   T3                        101 (60.1%)     97 (60.6%)     
   T4                        42 (25.0%)      32 (20.0%)     
  Distant metastases (M)                                    
   M0                        134 (79.8%)     124 (78.5%)    **0.4**
   M1                        34 (20.2%)      34 (21.5%)     
  Disease stages                                            
   I                         13 (7.6%)       15 (9.4%)      **0.6**
   II                        80 (47.1%)      81 (50.6%)     
   III                       42 (24.7%)      31 (19.4%)     
   IV                        35 (20.6%)      33 (20.6%)     
  MSI status                                                
   MSI                       26 (15.3%)      11 (6.9%)      **0.01**
   MSS                       144 (84.7%)     149 (93.1%)    
  RAS mutation                                              
   Presence                  16 (46.8%)      22 (57.9%)     **0.3**
   Absence                   36 (42.1%)      41 (53.2%)     

SD: standard deviation; LN: lymph node; MSI: microsatellite instability; MSS: microsatellite stable.

###### 

The clinical variables associated with overall survivals in the 330 colon cancer patients.

  Variables             Univariate analysis      Multivariate analysis                      
  --------------------- ------------------------ ----------------------- ------------------ -------
  Age (yr)                                                                                  
   ≥57                  79.77 (71.86-87.68)      0.4                                        
   \<57                 75.08 (66.59-83.56)                                                 
  Gender                                                                                    
   Female               69.09 (60.91-77.28)      0.003                   1.52 (1.03-3.08)   0.03
   Male                 86.19 (78.37-94.01)                                                 
  Tumor site                                                                                
   Right side           97.07 (85.97-108.17)     0.001                   1.79 (0.98-3.71)   0.05
   Left side            72.72 (66.27-79.16)                                                 
  Tumor stage                                                                               
   I-II                 89.48 (82.28-96.68)      0.000                   1.49 (1.29-2.82)   0.001
   III-IV               63.85 (55.48-72.22)                                                 
  LNR (mean)                                                                                
   1                    105.50 (100.36-110.64)   0.03                    2.04 (0.80-5.18)   0.1
   2                    92.38 (80.66-104.10)                                                
  TLN                                                                                       
   ≥12                  104.77 (96.26-113.27)    0.6                                        
   \<12                 101.72 (95.73-107.71)                                               
  Perineural invasion                                                                       
   Yes                  74.80 (58.63-90.96)      0.6                                        
   No                   82.64 (76.56-88.72)                                                 
  Vascular invasion                                                                         
   Yes                  88.47 (73.13-103.81)     0.1                                        
   No                   75.87 (69.73-82.02)                                                 
  MSI status                                                                                
   MSI                  109.71 (99.85-119.58)    0.001                   0.11 (0.06-1.04)   0.05
   MSS                  74.08 (68.00-80.16)                                                 
  RAS mutation                                                                              
   Presence             52.52 (40.918-64.133)    0.5                                        
   Absence              56.75 (42.057-71.452)                                               

CI: confidence interval; OS: overall survival; LNR: lymph node ratio; TLN: total lymph node; MSI: microsatellite instability; MSS: microsatellite stable.

[^1]: Academic Editor: Stamatios E. Theocharis
